曲妥珠单抗对乳腺癌根治术后HER-2阳性患者血清肿瘤标记物及免疫功能的影响  

Effects of Trastuzumab on Serum Tumor Markers and Immune Function in Patients with HER-2 Positive Breast Cancer after Radical Mastectomy

作　　者：石峰 SHI Feng(The Affliated Hospital of Xinyang Vocational and Techenical College,Xinyang 464000,Henan Province,China)

机构地区：[1]信阳职业技术学院附属医院,河南信阳464000

出　　处：《罕少疾病杂志》2025年第4期36-39,共4页Journal of Rare and Uncommon Diseases

摘　　要：目的分析曲妥珠单抗治疗乳腺癌根治术后人类表皮生长因子受体2(HER-2)阳性患者的疗效,并评估其血清肿瘤标记物水平变化及对免疫功能的影响。方法将我院于2021年8月至2023年4月收治的100例HER-2阳性患者临床诊治资料进行回顾性分析,均为根治术后化学药物治疗,并以治疗方案差异进行分组,对照组为蒽环类、环磷酰胺序贯紫杉类(AC-T)化疗方案,观察组则为AC-T+曲妥珠单抗协同治疗,观察两组治疗效果,以癌胚抗原(CEA)、糖类抗原125(CA-125)、糖类抗原153(CA-153)作为肿瘤标记物指标,以CD3+、CD4+、CD8+、CD4+/CD8+比值、B淋巴细胞、NK细胞作为免疫功能评估指标;比较两组治疗前后孕激素受体(PR)、雌激素受体状态,统计不良反应发生情况及心脏毒性反应。结果化疗结束后,观察组疾病治疗有效率高于对照组,且CEA、CA-153、CA-125水平均低于对照组,免疫指标中CD3+、CD4+、CD4+/CD8+比值及B淋巴细胞、NK细胞数值均高于对照组,CD8+水平低于对照组,差异均具有统计学意义(P<0.05);两组治疗后ER、PR阳性病例数及各项不良反应发生例数比较均无差异,同时左心室射血分数(LVEF)差值及差值幅度>10.00%例数比较亦无差异(P>0.05)。结论HER-2阳性乳腺癌患者在根治术后的化疗中应用曲妥珠单抗能明显获益,在提高疗效、控制肿瘤标志物水平的同时能改善机体免疫功能,避免化疗药物引起的免疫抑制,且不明显增加心脏毒性反应及其他类型不良反应。Objective To analyze the efficacy of trastuzumab in the treatment of human epidermal growth factor receptor 2(HER-2)positive patients after radical breast cancer surgery,and to evaluate the change of serum tumor marker levels and its effect on immune function.Methods A retrospective analysis was performed on the clinical diagnosis and treatment data of 100 HER-2 positive patients admitted to our hospital from August 2021 to April 2023.All patients were treated with chemotherapy after radical surgery and were divided into groups according to differences in treatment regimen.Control group was treated with anthracycline and cyclophosphamide sequential taxine(AC-T)chemotherapy.The observation group was treated with AC-T+trastuzumab.The therapeutic effects of the two groups were observed.Carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA-125)and carbohydrate antigen 53(CA-153)were used as tumor markers.CD3+,CD4+,CD8+,CD4+/CD8+ratio,B lymphocytes and NK cells were used as immune function evaluation indexes.The status of progesterone receptor(PR)and estrogen receptor before and after treatment were compared between the two groups,and the occurrence of adverse reactions and cardiotoxic reactions were analyzed.Results After chemotherapy,the effective rate of disease treatment in the observation group was higher than that in the control group,and the levels of CEA,CA-153 and CA-125 were lower than those in the control group.The ratios of CD3+,CD4+,CD4+/CD8+and the values of B lymphocytes and NK cells in the immune indexes were higher than those in the control group,and the levels of CD8+were lower than those in the control group.The differences were statistically significant(P<0.05).There was no difference in the number of ER and PR positive cases and the number of adverse reactions between the two groups after treatment,and there was no difference in the difference of left ventricular ejection fraction(LVEF)and the difference range>10.00%(P>0.05).Conclusion The application of trastuzumab in the chemotherapy of HER-

关 键 词：人类表皮生长因子受体2阳性 曲妥珠单抗 免疫功能 肿瘤标记物 心脏毒性 

分 类 号：R737.9[医药卫生—肿瘤]